PDCD1 and neoplasm: The above in vivo work not only supported the point of view that ORFV or ORFV/chemotherapy “dual-therapy”-induced pyroptosis can recruit CTLs to create an inflamed tumor microenvironment, but also suggested a way to make PD-1 blockade therapy applicable for killing immunologically “cold” tumors.